Literature DB >> 6403609

Recombinant interferon-gamma increases HLA-DR synthesis and expression.

T Y Basham, T C Merigan.   

Abstract

It has been shown that all three classes of interferons enhance the expression of the major histocompatibility class I antigens (HLA-A,B,C;H-2) on a wide variety of cell types (1-10). However, their effect on the expression of the class II antigens (HLA-DR, Ia), which play a major part in cellular interactions that initiate an immune response, is more controversial. The predominate findings have been that the interferons specifically increase the synthesis and expression of only the class I antigens (3, 4, 6, 8, 10, 11). We report here that recombinant interferon-gamma (IFN-gamma) increases the synthesis and expression of the HLA-DR (la-like) antigens as well as beta 2-microglobulin (beta 2-m), a low m.w. subunit of HLA, on human melanoma cells. No increase in HLA-DR was detected on these melanoma cells with leukocyte interferon (IFN-alpha) at doses 400 times higher than the maximum dose of IFN-gamma. These findings were extended to show that pure IFN-gamma also increases the expression of the HLA-DR antigens on normal peripheral blood monocytes, whereas recombinant IFN-alpha at a similar dose had little effect on the expression of this surface antigen. These findings suggest a specialized role for IFN-gamma in immune regulation in comparison with IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403609

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  139 in total

Review 1.  Cytokines as biological response modifiers.

Authors:  R C Rees
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

2.  The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.

Authors:  Y K Yoo; J B Gavaler; K Chen; T L Whiteside; D H van Thiel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.

Authors:  F Farace; C Mathiot; M Brandely; T Tursz; T Dorval; P Pouillart; F Triebel; T Hercend; W H Fridman
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

4.  Alternative activation in systemic juvenile idiopathic arthritis monocytes.

Authors:  Claudia Macaubas; Khoa D Nguyen; Ariana Peck; Julia Buckingham; Chetan Deshpande; Elizabeth Wong; Heather C Alexander; Sheng-Yung Chang; Ann Begovich; Yue Sun; Jane L Park; Kuang-Hung Pan; Richard Lin; Chih-Jian Lih; Erin M Augustine; Carolyn Phillips; Andreas V Hadjinicolaou; Tzielan Lee; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2011-12-28       Impact factor: 3.969

5.  The role of interferon gamma in the pathogenesis of Crohn's disease.

Authors:  T Sasaki; N Hiwatashi; H Yamazaki; M Noguchi; T Toyota
Journal:  Gastroenterol Jpn       Date:  1992-02

6.  Pre-diabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of rat MHC class II molecules in endocrine cells.

Authors:  B M Dean; R Walker; A J Bone; J D Baird; A Cooke
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts.

Authors:  T Collins; A J Korman; C T Wake; J M Boss; D J Kappes; W Fiers; K A Ault; M A Gimbrone; J L Strominger; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

8.  Identification of a major epitope by anti-interferon-γ autoantibodies in patients with mycobacterial disease.

Authors:  Chia-Hao Lin; Chih-Yu Chi; Han-Po Shih; Jing-Ya Ding; Chia-Chi Lo; Shang-Yu Wang; Chen-Yen Kuo; Chun-Fu Yeh; Kun-Hua Tu; Shou-Hsuan Liu; Hung-Kai Chen; Chen-Hsuan Ho; Mao-Wang Ho; Chen-Hsiang Lee; Hsin-Chin Lai; Cheng-Lung Ku
Journal:  Nat Med       Date:  2016-08-15       Impact factor: 53.440

9.  Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease.

Authors:  F Autschbach; G Schürmann; L Qiao; H Merz; R Wallich; S C Meuer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen.

Authors:  S J Gadd; O Majdic; W Kasinrerk; H Stockinger; D Maurer; R Eher; W Knapp
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.